Novo Nordisk launches a new cash-pay option for a leading diabetes drug, changing affordability dynamics for uninsured patients across the U.S.

(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo Nordisk, the maker of the GLP-1 drug Ozempic, announced Monday that U.S. patients can now get a month’s supply for just under $500. It typically carries a list price of around $1,000 a month.

In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump.

GLP-1 weight-loss drugs are creating “mortality slippage” in life insurance which is a costly problem that's forcing insurers to rethink how they underwrite.

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wego

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes